Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer

To examine the effect of β-cyclodextrin piroxicam treatment for priming of the uterus on the pregnancy outcome of IVF–embryo transfer (ET) programs. Prospective, randomized, double-blinded placebo-controlled clinical study. Large urban medical center. One hundred eighty-eight consecutive cycles of f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Fertility and sterility 2004-10, Vol.82 (4), p.816-820
Hauptverfasser: Moon, Hwa Sook, Park, Sea Hee, Lee, Ju Ok, Kim, Kyung Seo, Joo, Bo Sun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 820
container_issue 4
container_start_page 816
container_title Fertility and sterility
container_volume 82
creator Moon, Hwa Sook
Park, Sea Hee
Lee, Ju Ok
Kim, Kyung Seo
Joo, Bo Sun
description To examine the effect of β-cyclodextrin piroxicam treatment for priming of the uterus on the pregnancy outcome of IVF–embryo transfer (ET) programs. Prospective, randomized, double-blinded placebo-controlled clinical study. Large urban medical center. One hundred eighty-eight consecutive cycles of fresh IVF–ET and 78 cycles of frozen–thawed ET. The patients underwent IVF because of tubal, male infertility, unexplained, or endometriosis factors. They were randomly divided into treatment and control groups. In the treatment group, 94 cycles in fresh ET and 39 cycles in frozen–thawed ET the patients received an oral dose of 10 mg of piroxicam. In the control group, the same number cycles corresponding to the treatment group were treated with placebo. Both groups started piroxicam or placebo treatment 1–2 hours before ET. Patients and staff were blinded to the treatment. Implantation rate (IR) and pregnancy rate (PR). Piroxicam increased significantly IR (18.7%) and PR (46.8%) compared to the control group (8.6% and 27.6%, respectively) in fresh cycles. With the exception of an unexplained factor, patients with the tubal, male infertility, or endometriosis factor had significantly higher PR in the treatment group compared to the control group. The beneficial effect of piroxicam was found in patients less than 40 years old, but was not found in patients more than 40 years. In frozen–thawed cycles, there were statistically significant differences between the treatment group and the control group in IR (9.4% vs. 2.3%) and PR (25.6% vs. 7.7%), respectively. Our study showed that piroxicam increases IR and PR after IVF–ET in both fresh and frozen–thawed ET cycles. The beneficial effect seems to be more remarkable in patients less than 40 years old with tubal, male infertility, or endometriosis factors. These results suggest that piroxicam treatment before ET is very effective in the priming of a uterus suitable for embryo implantation. This is the first study to investigate the possible consequence of piroxicam for improving the PR after IVF–ET.
doi_str_mv 10.1016/j.fertnstert.2004.02.140
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66967520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0015028204011227</els_id><sourcerecordid>66967520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-14f0b3edbfe5fdb0e1af20a7474aa38f7f522e12a868d12e7a3479bfc8be27a03</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi1ERZeWv4B8gVvC2LHj7BEqvqRKvbRna-KMqVeJs9jewiLx38myK63EhcvM5XnfGT2McQG1ANG-29SeUom5LLOWAKoGWQsFz9hKaN1WutXNc7YCELoC2clL9jLnDQC0wsgX7FJo1UmjmxX7fZ8Iy0Sx8B-hPPJtSPPP4HDiPfk5EaepT_uZl4QxL0d5iG5JZMq8PBLfJvoWMbo9T1iIoy9_Ef4USpr54ckwhl9Ywhw5xuHftmt24XHM9Oq0r9jDp4_3N1-q27vPX2_e31ZOaSiVUB76hobek_ZDDyTQS0CjjEJsOm-8lpKExK7tBiHJYKPMuveu60kahOaKvT32btP8fUe52ClkR-OIkeZdtm27bo2WB7A7gi7NOSfydpvChGlvBdiDeruxZ_X2oN6CtIv6Jfr6dGPXTzScgyfXC_DmBGB2OPrFgQv5zLVi3SmtFu7DkaPFyFOgZLMLFB0NIZErdpjD_7_5A2XBq9k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66967520</pqid></control><display><type>article</type><title>Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Moon, Hwa Sook ; Park, Sea Hee ; Lee, Ju Ok ; Kim, Kyung Seo ; Joo, Bo Sun</creator><creatorcontrib>Moon, Hwa Sook ; Park, Sea Hee ; Lee, Ju Ok ; Kim, Kyung Seo ; Joo, Bo Sun</creatorcontrib><description>To examine the effect of β-cyclodextrin piroxicam treatment for priming of the uterus on the pregnancy outcome of IVF–embryo transfer (ET) programs. Prospective, randomized, double-blinded placebo-controlled clinical study. Large urban medical center. One hundred eighty-eight consecutive cycles of fresh IVF–ET and 78 cycles of frozen–thawed ET. The patients underwent IVF because of tubal, male infertility, unexplained, or endometriosis factors. They were randomly divided into treatment and control groups. In the treatment group, 94 cycles in fresh ET and 39 cycles in frozen–thawed ET the patients received an oral dose of 10 mg of piroxicam. In the control group, the same number cycles corresponding to the treatment group were treated with placebo. Both groups started piroxicam or placebo treatment 1–2 hours before ET. Patients and staff were blinded to the treatment. Implantation rate (IR) and pregnancy rate (PR). Piroxicam increased significantly IR (18.7%) and PR (46.8%) compared to the control group (8.6% and 27.6%, respectively) in fresh cycles. With the exception of an unexplained factor, patients with the tubal, male infertility, or endometriosis factor had significantly higher PR in the treatment group compared to the control group. The beneficial effect of piroxicam was found in patients less than 40 years old, but was not found in patients more than 40 years. In frozen–thawed cycles, there were statistically significant differences between the treatment group and the control group in IR (9.4% vs. 2.3%) and PR (25.6% vs. 7.7%), respectively. Our study showed that piroxicam increases IR and PR after IVF–ET in both fresh and frozen–thawed ET cycles. The beneficial effect seems to be more remarkable in patients less than 40 years old with tubal, male infertility, or endometriosis factors. These results suggest that piroxicam treatment before ET is very effective in the priming of a uterus suitable for embryo implantation. This is the first study to investigate the possible consequence of piroxicam for improving the PR after IVF–ET.</description><identifier>ISSN: 0015-0282</identifier><identifier>EISSN: 1556-5653</identifier><identifier>DOI: 10.1016/j.fertnstert.2004.02.140</identifier><identifier>PMID: 15482753</identifier><identifier>CODEN: FESTAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Biological and medical sciences ; Double-Blind Method ; Embryo Implantation - drug effects ; Embryo Transfer ; Estradiol - blood ; Female ; Fertilization in Vitro - methods ; Follicle Stimulating Hormone - blood ; Gynecology. Andrology. Obstetrics ; Humans ; Luteinizing Hormone - blood ; Male ; Medical sciences ; Ovulation Induction - methods ; Piroxicam - therapeutic use ; Pregnancy ; pregnancy outcome ; Pregnancy Rate ; Prospective Studies ; Treatment Outcome ; uterine contractility ; β-Cyclodextrin piroxicam</subject><ispartof>Fertility and sterility, 2004-10, Vol.82 (4), p.816-820</ispartof><rights>2004 American Society for Reproductive Medicine</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-14f0b3edbfe5fdb0e1af20a7474aa38f7f522e12a868d12e7a3479bfc8be27a03</citedby><cites>FETCH-LOGICAL-c450t-14f0b3edbfe5fdb0e1af20a7474aa38f7f522e12a868d12e7a3479bfc8be27a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0015028204011227$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16198454$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15482753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moon, Hwa Sook</creatorcontrib><creatorcontrib>Park, Sea Hee</creatorcontrib><creatorcontrib>Lee, Ju Ok</creatorcontrib><creatorcontrib>Kim, Kyung Seo</creatorcontrib><creatorcontrib>Joo, Bo Sun</creatorcontrib><title>Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer</title><title>Fertility and sterility</title><addtitle>Fertil Steril</addtitle><description>To examine the effect of β-cyclodextrin piroxicam treatment for priming of the uterus on the pregnancy outcome of IVF–embryo transfer (ET) programs. Prospective, randomized, double-blinded placebo-controlled clinical study. Large urban medical center. One hundred eighty-eight consecutive cycles of fresh IVF–ET and 78 cycles of frozen–thawed ET. The patients underwent IVF because of tubal, male infertility, unexplained, or endometriosis factors. They were randomly divided into treatment and control groups. In the treatment group, 94 cycles in fresh ET and 39 cycles in frozen–thawed ET the patients received an oral dose of 10 mg of piroxicam. In the control group, the same number cycles corresponding to the treatment group were treated with placebo. Both groups started piroxicam or placebo treatment 1–2 hours before ET. Patients and staff were blinded to the treatment. Implantation rate (IR) and pregnancy rate (PR). Piroxicam increased significantly IR (18.7%) and PR (46.8%) compared to the control group (8.6% and 27.6%, respectively) in fresh cycles. With the exception of an unexplained factor, patients with the tubal, male infertility, or endometriosis factor had significantly higher PR in the treatment group compared to the control group. The beneficial effect of piroxicam was found in patients less than 40 years old, but was not found in patients more than 40 years. In frozen–thawed cycles, there were statistically significant differences between the treatment group and the control group in IR (9.4% vs. 2.3%) and PR (25.6% vs. 7.7%), respectively. Our study showed that piroxicam increases IR and PR after IVF–ET in both fresh and frozen–thawed ET cycles. The beneficial effect seems to be more remarkable in patients less than 40 years old with tubal, male infertility, or endometriosis factors. These results suggest that piroxicam treatment before ET is very effective in the priming of a uterus suitable for embryo implantation. This is the first study to investigate the possible consequence of piroxicam for improving the PR after IVF–ET.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Embryo Implantation - drug effects</subject><subject>Embryo Transfer</subject><subject>Estradiol - blood</subject><subject>Female</subject><subject>Fertilization in Vitro - methods</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Luteinizing Hormone - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Ovulation Induction - methods</subject><subject>Piroxicam - therapeutic use</subject><subject>Pregnancy</subject><subject>pregnancy outcome</subject><subject>Pregnancy Rate</subject><subject>Prospective Studies</subject><subject>Treatment Outcome</subject><subject>uterine contractility</subject><subject>β-Cyclodextrin piroxicam</subject><issn>0015-0282</issn><issn>1556-5653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi1ERZeWv4B8gVvC2LHj7BEqvqRKvbRna-KMqVeJs9jewiLx38myK63EhcvM5XnfGT2McQG1ANG-29SeUom5LLOWAKoGWQsFz9hKaN1WutXNc7YCELoC2clL9jLnDQC0wsgX7FJo1UmjmxX7fZ8Iy0Sx8B-hPPJtSPPP4HDiPfk5EaepT_uZl4QxL0d5iG5JZMq8PBLfJvoWMbo9T1iIoy9_Ef4USpr54ckwhl9Ywhw5xuHftmt24XHM9Oq0r9jDp4_3N1-q27vPX2_e31ZOaSiVUB76hobek_ZDDyTQS0CjjEJsOm-8lpKExK7tBiHJYKPMuveu60kahOaKvT32btP8fUe52ClkR-OIkeZdtm27bo2WB7A7gi7NOSfydpvChGlvBdiDeruxZ_X2oN6CtIv6Jfr6dGPXTzScgyfXC_DmBGB2OPrFgQv5zLVi3SmtFu7DkaPFyFOgZLMLFB0NIZErdpjD_7_5A2XBq9k</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Moon, Hwa Sook</creator><creator>Park, Sea Hee</creator><creator>Lee, Ju Ok</creator><creator>Kim, Kyung Seo</creator><creator>Joo, Bo Sun</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041001</creationdate><title>Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer</title><author>Moon, Hwa Sook ; Park, Sea Hee ; Lee, Ju Ok ; Kim, Kyung Seo ; Joo, Bo Sun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-14f0b3edbfe5fdb0e1af20a7474aa38f7f522e12a868d12e7a3479bfc8be27a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Embryo Implantation - drug effects</topic><topic>Embryo Transfer</topic><topic>Estradiol - blood</topic><topic>Female</topic><topic>Fertilization in Vitro - methods</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Luteinizing Hormone - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Ovulation Induction - methods</topic><topic>Piroxicam - therapeutic use</topic><topic>Pregnancy</topic><topic>pregnancy outcome</topic><topic>Pregnancy Rate</topic><topic>Prospective Studies</topic><topic>Treatment Outcome</topic><topic>uterine contractility</topic><topic>β-Cyclodextrin piroxicam</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moon, Hwa Sook</creatorcontrib><creatorcontrib>Park, Sea Hee</creatorcontrib><creatorcontrib>Lee, Ju Ok</creatorcontrib><creatorcontrib>Kim, Kyung Seo</creatorcontrib><creatorcontrib>Joo, Bo Sun</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fertility and sterility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moon, Hwa Sook</au><au>Park, Sea Hee</au><au>Lee, Ju Ok</au><au>Kim, Kyung Seo</au><au>Joo, Bo Sun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer</atitle><jtitle>Fertility and sterility</jtitle><addtitle>Fertil Steril</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>82</volume><issue>4</issue><spage>816</spage><epage>820</epage><pages>816-820</pages><issn>0015-0282</issn><eissn>1556-5653</eissn><coden>FESTAS</coden><abstract>To examine the effect of β-cyclodextrin piroxicam treatment for priming of the uterus on the pregnancy outcome of IVF–embryo transfer (ET) programs. Prospective, randomized, double-blinded placebo-controlled clinical study. Large urban medical center. One hundred eighty-eight consecutive cycles of fresh IVF–ET and 78 cycles of frozen–thawed ET. The patients underwent IVF because of tubal, male infertility, unexplained, or endometriosis factors. They were randomly divided into treatment and control groups. In the treatment group, 94 cycles in fresh ET and 39 cycles in frozen–thawed ET the patients received an oral dose of 10 mg of piroxicam. In the control group, the same number cycles corresponding to the treatment group were treated with placebo. Both groups started piroxicam or placebo treatment 1–2 hours before ET. Patients and staff were blinded to the treatment. Implantation rate (IR) and pregnancy rate (PR). Piroxicam increased significantly IR (18.7%) and PR (46.8%) compared to the control group (8.6% and 27.6%, respectively) in fresh cycles. With the exception of an unexplained factor, patients with the tubal, male infertility, or endometriosis factor had significantly higher PR in the treatment group compared to the control group. The beneficial effect of piroxicam was found in patients less than 40 years old, but was not found in patients more than 40 years. In frozen–thawed cycles, there were statistically significant differences between the treatment group and the control group in IR (9.4% vs. 2.3%) and PR (25.6% vs. 7.7%), respectively. Our study showed that piroxicam increases IR and PR after IVF–ET in both fresh and frozen–thawed ET cycles. The beneficial effect seems to be more remarkable in patients less than 40 years old with tubal, male infertility, or endometriosis factors. These results suggest that piroxicam treatment before ET is very effective in the priming of a uterus suitable for embryo implantation. This is the first study to investigate the possible consequence of piroxicam for improving the PR after IVF–ET.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15482753</pmid><doi>10.1016/j.fertnstert.2004.02.140</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0015-0282
ispartof Fertility and sterility, 2004-10, Vol.82 (4), p.816-820
issn 0015-0282
1556-5653
language eng
recordid cdi_proquest_miscellaneous_66967520
source MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Adult
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Biological and medical sciences
Double-Blind Method
Embryo Implantation - drug effects
Embryo Transfer
Estradiol - blood
Female
Fertilization in Vitro - methods
Follicle Stimulating Hormone - blood
Gynecology. Andrology. Obstetrics
Humans
Luteinizing Hormone - blood
Male
Medical sciences
Ovulation Induction - methods
Piroxicam - therapeutic use
Pregnancy
pregnancy outcome
Pregnancy Rate
Prospective Studies
Treatment Outcome
uterine contractility
β-Cyclodextrin piroxicam
title Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T15%3A38%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20with%20piroxicam%20before%20embryo%20transfer%20increases%20the%20pregnancy%20rate%20after%20in%20vitro%20fertilization%20and%20embryo%20transfer&rft.jtitle=Fertility%20and%20sterility&rft.au=Moon,%20Hwa%20Sook&rft.date=2004-10-01&rft.volume=82&rft.issue=4&rft.spage=816&rft.epage=820&rft.pages=816-820&rft.issn=0015-0282&rft.eissn=1556-5653&rft.coden=FESTAS&rft_id=info:doi/10.1016/j.fertnstert.2004.02.140&rft_dat=%3Cproquest_cross%3E66967520%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66967520&rft_id=info:pmid/15482753&rft_els_id=S0015028204011227&rfr_iscdi=true